By 23andMe
Report updated May 7, 2026
23andMe - DNA Testing
For adults interested in personal genetic discovery, ancestry mapping, and proactive health management.
23andMe - DNA Testing is an established health & fitness app that is free with in-app purchases. With a 4.8/5 rating from 605.7K reviews, it shows polarized user reception. Users particularly appreciate detailed ancestry and health reports provide high value for personal discovery and familial connection, though aggressive monetization and pay-to-view gating of previously free features frustrate long-term legacy users remains a common concern.
What is 23andMe - DNA Testing?
23andMe is a health and ancestry DNA testing app for adults, providing genetic insights and clinical-grade health reporting on iOS and Android.
Users hire 23andMe to resolve questions about heritage and health risks, but the shift to subscription-gated features forces a trade-off between long-term data access and recurring costs.
Current Momentum
v5.312 · 1w ago
Active- Shipped Historical Matches feature.
- Added Biological Age biomarker feature.
- Enabled non-binary gender account options.
Active Nemesis
Ancestry: Family History & DNA
By Ancestry.com
Other Rivals
7-Day Rank Pulse 🇺🇸
Health & FitnessNo ranking data
Rating Pulse 🇺🇸
Recent User MoodAI-powered deep analysis surfacing high-signal insights. Still in beta, accuracy improves daily. For informational purposes only.
What makes this app unique?
What Does It Look Like?
How Is The App's Momentum Right Now?
Loading...
What Are The Key Features?
Genetic breakdown across 4,500+ regions
FDA-cleared genetic health risk and carrier status
Physician-initiated exome sequencing and blood testing
How much does it cost?
- Ancestry $79
- Premium $80
- Total Health $399
Tiered pricing anchors on entry-level kits with subscription revenue driven by ongoing health and clinical services.
Who Built It?
Providing personal genetic insights for ancestry and health management. Helping users navigate their DNA data through actionable reports and clinical tools.
Portfolio
1
Apps
Who is 23andMe?
23andMe leverages a massive proprietary genetic database to maintain a dominant position in the consumer genomics market, creating a significant barrier to entry for smaller competitors. The company is currently navigating a strategic pivot, attempting to transition from a pure-play ancestry discovery service into a broader health-tech platform by gating legacy features behind subscription tiers. This shift creates a notable tension between their established user base and the need to monetize long-term engagement through recurring revenue models. Their credibility is anchored in their research institute's published studies, which provide a scientific foundation for their health-focused product offerings.
Who is 23andMe for?
- Adults seeking personal genetic discovery
- Ancestry mapping
- Proactive health management
Portfolio momentum
Released 12 updates in the last 6 months for their single active application, indicating a high frequency of maintenance and feature iteration.
What do users think recently?
High confidence · 100 reviews analyzed · Based on 100 reviews. Signal may be noisy.
How did the latest release land?
What is the recent mood?
Recent user voice shows a mixed sentiment. Users appreciate detailed ancestry and health reports provide high value for personal discovery and familial connection, but report aggressive monetization and pay-to-view gating of previously free features frustrate long-term legacy users.
What Users Love
What Frustrates Users
What Users Want
What is the competitive landscape for 23andMe - DNA Testing?
How's The Health & Fitness Market?
How does it evolve in the Health & Fitness market?
23andMe maintains a high-rating baseline of 4.8 across 605,688 total reviews, anchoring its position as the primary health-focused DNA platform. The gap between its clinical-grade reporting and Ancestry's record-searching indicates a strategic divergence in user retention mechanics.
| Country | Category | Chart | Rank | Change |
|---|---|---|---|---|
| 🇨🇾 Cyprus | Health & Fitness | iOSFree | #68 | NEW |
| 🇳🇴 Norway | Health & Fitness | AndroidFree | #161 | NEW |
The rivals identified
The Nemesis
Head to Head
The target app must decide whether to compete on genealogy depth or double down on clinical health utility to differentiate from Ancestry's broad-spectrum platform.
What sets 23andMe - DNA Testing apart
Provides a more direct, clinically-oriented focus on genetic health insights and personalized wellness reporting.
Offers a streamlined user experience that prioritizes actionable health data over complex family tree building.
What's Ancestry: Family History & DNA's Edge
Deep integration of historical records creates a long-term retention loop that health-only apps lack.
Superior community-driven family tree features encourage users to continuously contribute and expand their data.
Contenders
Aggressive release schedule of six updates in six months signals rapid iteration on user feedback.
Focuses heavily on photo enhancement and colorization tools to drive viral social sharing of ancestry.
Peers
everlywell
★4.9 (9.5K)Everly Health, Inc.
Operates in the health-testing space, focusing on diagnostic lab results rather than ancestry.
Specializes in at-home diagnostic testing kits for specific health markers rather than broad genetic mapping.
Provides a more clinical, lab-focused user experience compared to the lifestyle-oriented 23andMe interface.
InsideTracker
★3.4 (337)Segterra Inc
Targets the performance-optimization niche within the broader health and fitness category.
Integrates blood biomarker analysis with genetic data to provide highly specific lifestyle and nutrition recommendations.
Positions itself as a high-performance coaching tool for athletes rather than a general ancestry discovery app.
New Kids on the Block
Nebula
★4.8 (13.3K)Standard
An emerging platform with high engagement potential, though currently positioned in the entertainment space.
Utilizes a creator-focused subscription model that could disrupt traditional content-heavy health and wellness platforms.
Demonstrates high user satisfaction through a unique content-first delivery mechanism that prioritizes creator-led discovery.
The outtake for 23andMe - DNA Testing
Strengths to defend, gaps to attack
Core Strengths
- Research-driven data pipeline fuels scientific discovery
- Clinical-grade health reporting differentiates from genealogy-first rivals
- High-volume genetic database creates a barrier to entry
Critical Frictions
- Premium tier pricing above category median
- 0.7★ Android-iOS rating gap
- Frequent authentication loops in the latest release
Growth Levers
- Untapped B2B education partnerships
- Wearable integration for longitudinal health tracking
Market Threats
- EU data-minimisation tightening
- Ancestry's record-searching retention loop
- User distrust regarding AI-generated reports
What are the next best moves?
Audit authentication flows because login friction is a top-3 complaint → reduce churn among legacy users
Users report being locked out of accounts or forced to re-register repeatedly.
Trade-off: Push the wearable companion app sprint to Q3.
Clarify genetic group labels because users struggle to interpret results accurately → reduce support volume
Users request definitions for terms like very close or distant to avoid misinterpretation.
Trade-off: Pause the trait-data feedback mechanism project.
A counter-intuitive read
The shift toward subscription-gated health insights is not a failure of monetization, but a necessary transition to fund the high-cost clinical infrastructure required to outpace genealogy-only competitors.
Feature Gaps vs Competitors
- Deep genealogical record-searching (available in Ancestry but missing here)
Key Takeaways
23andMe leads in clinical-grade genetic insights, but aggressive paywalling of legacy features risks alienating the core user base, so the PM must prioritize authentication stability to protect long-term retention.
Where Is It Heading?
Mixed Signals
The DNA testing market is consolidating around specialized health-tracking and deep genealogy records, leaving 23andMe in a high-stakes position between clinical utility and lifestyle discovery. The company must balance its research-driven revenue model with user privacy expectations to prevent further sentiment decline.
Aggressive monetization of legacy features triggers user frustration, which compounds the churn risk among long-term legacy customers.
Consistent addition of health-focused features like Biological Age biomarkers signals active investment in clinical-grade utility over maintenance mode.